Cargando…
Early mortality factors in immune checkpoint inhibitor monotherapy for advanced or metastatic non-small cell lung cancer
PURPOSE: Immune checkpoint inhibitors (ICI) are a promising treatment, but may cause hyperprogressive disease and early death. The present study investigated early mortality factors in ICI monotherapy for lung cancer. PATIENTS AND METHODS: We retrospectively reviewed all patients diagnosed with adva...
Autores principales: | Takeuchi, Eiji, Kondo, Kensuke, Okano, Yoshio, Kunishige, Michihiro, Kondo, Yoshihiro, Kadota, Naoki, Machida, Hisanori, Hatakeyama, Nobuo, Naruse, Keishi, Ogino, Hirokazu, Nokihara, Hiroshi, Shinohara, Tsutomu, Nishioka, Yasuhiko |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10314836/ https://www.ncbi.nlm.nih.gov/pubmed/35871700 http://dx.doi.org/10.1007/s00432-022-04215-7 |
Ejemplares similares
-
Pretreatment eosinophil counts as a predictive biomarker in non‐small cell lung cancer patients treated with immune checkpoint inhibitors
por: Takeuchi, Eiji, et al.
Publicado: (2023) -
A single dose of pembrolizumab treatment causing a profound and durable response in lung cancer
por: Kondo, Yoshihiro, et al.
Publicado: (2022) -
Late‐onset acute type 1 diabetes mellitus 7 months after discontinuation of pembrolizumab against lung cancer
por: Ichihara, Seiya, et al.
Publicado: (2022) -
Non‐small cell lung cancer with
EGFR
(L858R and E709X) and CNNB1 mutations responded to afatinib
por: Kunishige, Michihiro, et al.
Publicado: (2022) -
Dramatic response to immunochemotherapy followed by salvage surgery in an elderly lung cancer patient
por: Okano, Yoshio, et al.
Publicado: (2021)